GMP Dexamethasone Phosphate Injection 4mg/Ml
Dexamethasone 4 mg/ml solution for
injection is recommended for systemic administration by intravenous or
intramuscular injection when oral therapy is not feasible or desirable
in the following conditions.
Primary or secondary adrenocortical insufficiency
(Hydrocortisone or cortisone is the first choice, but synthetic analogues may be used with mineralocorticoids where applicable and, in infancy, mineralocorticoid supplementation is particularly important)
Dexamethasone 4 mg/ml solution for injection may be used in the treatment of non-endocrine
corticosteroid-responsive conditions, including:
Allergy and anaphylaxis
Angioneurotic oedema and anaphylaxis
Crohn's disease and ulcerative colitis
Infection (with appropriate chemotherapy)
Miliary tuberculosis and endotoxic shock
Raised intracranial pressure secondary to cerebral tumours and infantile spasms
Bronchial asthma and aspiration pneumonitis
Toxic epidermal necrolysis
Adjunctive treatment where high pharmacological doses are needed. Treatment is an adjunct to and not a substitute for, specific and supportive measures the patient may require. Dexamethasone has been shown to be beneficial when used in the early treatment of shock, but it may not influence overall survival.
In palliative care, patients receiving corticosteroids for symptoms such as fatigue, anorexia, refractory nausea and vomiting or adjuvant analgesia and symptomatic treatment of cord compression or raised intracranial pressure, dexamethasone 4 mg/ml solution for injection may be
administered subcutaneously (see section 4.2) as an alternative to the oral route when the latter is unacceptable or no longer feasible.
Dexamethasone 4 mg/ml solution for injection is suitable for intraarticular or soft-tissue injection
as adjunctive therapy for short-term administration in:
Such as carpal tunnel syndrome and tenosynovitis
Such as rheumatoid arthritis and osteoarthritis with an inflammatory component
Dexamethasone 4 mg/ml solution for injection may be injected intralesionally in selected skin
disorders such as cystic acne vulgaris, localised lichen simplex, and keloids.